Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,207 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID Clear all
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19

NCT05042193
View directory record Official record
Conditions
SARS-CoV-2 Acute Respiratory Disease
Interventions
SARS-CoV-2
Other
Lead sponsor
Everly Health
Industry
Eligibility
18 Years and older
Enrollment
1,883 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 27, 2026, 1:29 AM EDT
Not listed No phase listed Observational

IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.

NCT04402814
View directory record Official record
Conditions
SARS-CoV 2
Interventions
Clungene rapid test cassette
Diagnostic Test
Lead sponsor
Fadi Haddad, M.D.
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 27, 2026, 1:29 AM EDT
Completed No phase listed Observational Results available

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

NCT07072793
View directory record Official record
Conditions
COVID-19 (Coronavirus Disease 2019)
Interventions
nirmatrelvir-ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
131,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 27, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients

NCT04421404
View directory record Official record
Conditions
COVID-19, Sars-CoV2
Interventions
COVID-19 Convalescent Plasma (CCP), Placebo
Biological
Lead sponsor
Priscilla Hsue, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 27, 2026, 1:29 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A CHW Intervention to Identify and Decrease Barriers to COVID 19 Testing & Vaccination

NCT05473936
View directory record Official record
Conditions
Vaccine Hesitancy, COVID-19 Testing, Community Health Workers
Interventions
Community Health Worker led curriculum
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
16 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 27, 2026, 1:29 AM EDT
Completed Not applicable Interventional

RECOVER-ENERGIZE Platform Protocol

NCT06404047
View directory record Official record
Conditions
Long COVID, Long Covid19, Long Covid-19
Interventions
Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 27, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

NCT04401293
View directory record Official record
Conditions
Sars-CoV2, COVID
Interventions
Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 27, 2026, 1:29 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Northwest Therapies Trauma Psilocybin Study Compassionate Use Study

NCT05042466
View directory record Official record
Conditions
Trauma, Nervous System
Interventions
Trauma
Drug
Lead sponsor
NWTraumatherapies
Network
Eligibility
21 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 27, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT07300839
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 Vaccine, Placebo
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
50 Years to 64 Years
Enrollment
5,240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
196
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 1:29 AM EDT
Not listed No phase listed Observational

Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients

NCT04465981
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection
Interventions
Sampling
Diagnostic Test
Lead sponsor
INanoBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Oct 27, 2026, 1:29 AM EDT
Terminated Phase 4 Interventional Results available

UPMC OPTIMISE-C19 Trial, a COVID-19 Study

NCT04790786
View directory record Official record
Conditions
Covid19
Interventions
Lilly Bamlanivimab, Regeneron Casirivimab + Imdevimab, Lilly Bamlanivimab + Etesevimab, Sotrovimab, Bebtelovimab
Biological
Lead sponsor
Erin McCreary
Other
Eligibility
12 Years to 120 Years
Enrollment
4,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 27, 2026, 1:29 AM EDT
Withdrawn Phase 2 Interventional

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

NCT05545319
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized
Interventions
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cooperstown, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 27, 2026, 1:29 AM EDT
Completed No phase listed Observational

Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)

NCT05074719
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19, Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
10 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 27, 2026, 1:29 AM EDT
Completed No phase listed Observational

COVID-19 Endoscopy Survey

NCT04342637
View directory record Official record
Conditions
COVID-19
Interventions
Practice details
Other
Lead sponsor
Al-Azhar University
Other
Eligibility
30 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Albertson, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 27, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Aggrenox To Treat Acute Covid-19

NCT04410328
View directory record Official record
Conditions
Covid19
Interventions
Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care, Standard of care
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
19 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 27, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial

NCT04472611
View directory record Official record
Conditions
SARS-CoV-2
Interventions
Standard of Care (SOC) and Colchicine+Rosuvastatin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Bridgeport, Connecticut • Greenwich, Connecticut • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 27, 2026, 1:29 AM EDT
Completed No phase listed Observational

Coagulation Changes Associated With COVID-19 Infection

NCT04460664
View directory record Official record
Conditions
COVID, Disseminated Intravascular Coagulation, Coagulation Disorder
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 27, 2026, 1:29 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

NCT04889209
View directory record Official record
Conditions
COVID-19
Interventions
Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
867 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
10
States / cities
Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 27, 2026, 1:29 AM EDT
Recruiting Phase 2 Interventional

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

NCT07021794
View directory record Official record
Conditions
Post-COVID / Long-COVID
Interventions
Placebo, Sipavibart
Drug · Biological
Lead sponsor
Nancy Klimas
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized

NCT05799495
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
PF-07817883, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
53
States / cities
Cullman, Alabama • Phoenix, Arizona • Surprise, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 27, 2026, 1:29 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Trial of Hydroxychloroquine In Covid-19 Kinetics

NCT04353271
View directory record Official record
Conditions
Covid 19, Corona Virus Infection
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of South Alabama
Other
Eligibility
19 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Oct 27, 2026, 1:29 AM EDT
Completed No phase listed Observational

Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis

NCT04834401
View directory record Official record
Conditions
Multiple Sclerosis, Covid19
Interventions
Not listed
Lead sponsor
St. Barnabas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Livingston, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 27, 2026, 1:29 AM EDT
Completed No phase listed Observational

A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois

NCT04611230
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 27, 2026, 1:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

COVID-19 Self-testing IMPROVE

NCT06576167
View directory record Official record
Conditions
COVID-19
Interventions
IMPROVE
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
1,277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 27, 2026, 1:29 AM EDT